In this issue of Danish Pharmacovigilance Update:
- Use of medicines involving a risk of serious and life-threatening skin reactions
- European Medicines Agency (EMA) to investigate the possible connection between orlistat and rare cases of severe liver toxicity
- EMA completes review of peritoneal dialysis solutions from Baxter A/S
- Product information for Revlimid® to be updated
- The Danish Medicines Agency has received a report of a death in connection with use of the smoking cessation product Champix®
- List of medicines most frequently involved in serious adverse drug events to help minimise risks in the medication process
- New restrictions in use, further contraindications and warnings for Multaq® (dronedarone)
- Adverse reactions in connection with the childhood immunisation programme in the first half of 2011
Download the newsletter in the box to the right.
